|
Aethlon Discloses CEO Interviews- Mr. Joyce discussed
issues related to Avian Flu, including the potential use of the Aethlon
Hemopurifier(TM) as a treatment countermeasure.
SAN DIEGO--March 24, 2006--Aethlon Medical, Inc. (OTCBB: AEMD), a pioneer in
developing therapeutic devices for infectious disease, disclosed today that
Chairman and CEO, James A. Joyce has been interviewed as a featured guest on
"Adelines's Cronicles,", a national radio program broadcast to more than
1,000 stations on the National Radio Network and Cable Radio Network. Mr.
Joyce discussed issues related to Avian Flu, including the potential use of
the Aethlon Hemopurifier(TM) as a treatment countermeasure.
About Aethlon Medical
Aethlon Medical is developing the first medical device to treat infectious
disease. The device, known as the Hemopurifier(TM), is a broad-spectrum
treatment countermeasure against drug and vaccine resistant bioweapons,
naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic
infectious disease targets including Hepatitis-C (HCV) and the Human
Immunodeficiency Virus (HIV). Aethlon has also initiated research on a
second generation Hemopurifier(TM) that targets the capture of growth
factors inherent in the spread of Cancer.
www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks
and uncertainties. Such forward-looking statements involve assumptions,
known and unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of Aethlon Medical, Inc to be
materially different from any future results, performance, or achievements
expressed or implied by the forward-looking statements. Such potential risks
and uncertainties include, without limitation, the Company's ability to
raise capital when needed, the Company's ability to complete the development
of its planned products, the ability of the Company to obtain FDA and other
regulatory approvals permitting the sale of its products, the Company's
ability to manufacture its products and provide its services, the impact of
government regulations, patent protection on the Company's proprietary
technology, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such
instances, actual results could differ materially as a result of a variety
of factors, including the risks associated with the effect of changing
economic conditions and other risk factors detailed in the Company's
Securities and Exchange Commission filings.
Contact:
Aethlon Medical, Inc.
Jeff Richardson, 858.459.7800 x302
jrichardson@aethlonmedical.com
James A. Joyce, 858.459.7800 x301
jj@aethlonmedical.com
Aethlon Medical, Inc.
|
|
